H2020TRL 3Biomed

B2B

Modelling spontaneous breast cancer metastasis to the bone with a new 3D device

Project details

GA NUMBER

801159

PROJECT TYPE

FET OPEN

FUNDING

€3.8 m

STARTING DATE

1 July 2018

DURATION

4 years and 6 months

Innovative 3D organ on chip based model to study breast to bone metastasis formation

A major obstacle in preventing high breast cancer mortality is the limited understanding of how breast cancer cells metastasise to bone sites. The EU-funded B2B project aims to develop a first-of-a-kind 3D model of spontaneous breast cancer metastasis to the bone for the purposes of basic research and drug screening in a physiological context. It will overcome the drawbacks of traditional in vitro and in vivo models by mimicking the physiological system of connected organs. Cultured breast cancer organoids will be connected in vitro to marrow-containing bone tissue via a fluidic system involving the self-assembled capillaries of those organoids and an artificial 3D bioprinted macro-vascular tree of branching blood vessels.

Partners

Consiglio Nazionale delle ricercheUniversität BaselUniversiteit MaastrichtCambridge Innovation Technologies Consulting LimitedReact4life SrlINsocietyDe Erasmus Universiteit Medisch Centrum RotterdamBioEmission Technology SolutionsEidgenoessische Technische Hochschule Zuerich

Our role

What we did to make this project TRULY INNOVATIVE.

  • Innovation Management

 

  • Communication & Dissemination activities including Data Management

Milestones step by step

A quick overview of the goals achieved by working on this project.

Gallery

The cost to develop prototype development and scientific validation would have been a major bottleneck if it hadn’t been for the EU funding.

Silvia Scaglione - React4Life & CNR